Manufacturer
AstraZeneca
Contents
Budesonide 160 mcg, formoterol 4.5 mcg
Indication
Asthma: Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β2-agonist) is appropriate. COPD: Symptomatic treatment of patients w/ severe COPD (FEV1 <50% predicted normal) & a history of repeated exacerbations, who have significant symptoms despite regular therapy w/ long-acting bronchodilators.
Instruction
Asthma Maintenance therapy Adult ≥18 yr 1-2 inhalations twice daily. Some patients may require up to a max of 4 inhalations twice daily. Adolescent 12-17 yr 1-2 inhalations twice daily.
Drug interaction
Itraconazole, ritonavir, CYP3A4 inhibitors. β-blockers (including eye drops), potent CYP3A4 inhibitors. Quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine), MAOIs (furazolidone & procarbazine) & TCAs, anesth, digitalis, L-dopa, L-thyroxine, oxytocin & alcohol, furazolidone, rocarbazine, anaesth w/ halogenated hydrocarbons.
Malaysia
